New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
08:41 EDTHEBHemispherx analysis of new data on protection from pulmonary damage by H5N1
Hemispherx Biopharma announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21 at the Keystone Symposia Conference on Pathogenesis of Respiratory Viruses entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus, or H5N1, by Low Dose Natural Human IFN- Administered to the Buccal Mucosa." The global threat of an influenza pandemic emerging from avian H5N1 and H7N9 influenza viruses that are highly pathogenic for humans has mobilized a variety of efforts to mitigate the potential devastating human and economic consequences. The study demonstrated a dose-dependent sparing of the H5N1 induced pulmonary damage. Clinical studies will be required to validate similar results in humans from highly pathogenic H5N1, H7N9, or similar emerging avian influenza viruses. Thus, both H5N1 influenza virus (the subject of collaboration with the Osterhaus group) and H7N9 influenza virus (the subject of ongoing collaboration with Prof. J. Richt's group at the Center of Excellence for Emerging and Zoonotic Animal Diseases, Kansas State University are susceptible to Alferon N treatment in various model systems. The latter work was conducted at research facilities designed to enhance the capability of the US Department of Homeland Security.
News For HEB From The Last 14 Days
Check below for free stories on HEB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
08:41 EDTHEBHemispherx achieves high ranking in sensitivity testing against MERS/SARS
Subscribe for More Information
July 14, 2014
08:39 EDTHEBHemispherx, Bioclones announce strategic alliance
Hemispherx Biopharma announced a strategic alliance to develop multiple projects with Bioclones. Bioclones and Hemispherx concluded strategic discussions in Johannesburg with three principal goals; initiating studies utilizing Ampligen as a potential adjuvant enhancement of Bioclones' therapeutic cancer vaccine, currently in clinical trials in Cape Town, including pre-clinical studies followed, potentially, by a Phase 1 clinical trial; seeking South African Medicine's Control Council approval to conduct trials using Alferon to eradicate the HIV virus in patients highly responsive to anti-retroviral therapy; and initiating a joint effort to obtain commercial registration of both Ampligen and Alferon in the South African markets. The first clinical program builds on the Bioclones patented therapeutic human dendritic cell, or DC, cancer vaccination approach. This invention provides a method of producing mature DCs in vitro, which comprises the step of culturing the immature DCs, thereafter exposing said cells to tumor antigens before administration to patients. The team has successfully obtained the necessary Ethics approval to use Ampligen as an adjuvant in the Bioclones pre-clinical cancer immunotherapy program utilizing patient derived samples. Pre-clinical studies will be directed towards the potential treatment of breast cancer in particular, followed by prostate cancer. These studies are part of the effort to develop patient-specific DC immunotherapy vaccines against breast cancer and prostate cancer, which elicit an immune response that will target and kill cancer cells. Human DCs matured with Ampligen and transfected with autologous tumor-specific mRNA are designed to elicit a potent and autologous tumoricidal antigen-specific cytotoxic response to the cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use